Drugs / VVX001
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03625934 | Aug 2018 → Sep 2023 | hepatitis B virus infection | Viravaxx AG | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | VVX001 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03625934 ↗ |
| Route | Subcutaneous | “5 s.c. injections of 20 micrograms of VVX001 four weeks apart” NCT03625934 ↗ |